Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06265688 | First In Human Study of CX-2051 in Advanced Solid Tumors | PHASE1 | RECRUITING | 160 | — | — | Apr 2, 2024 | Mar 31, 2029 | May 19, 2026 | 7 | United States |
The number of participants experiencing a dose-limiting toxicity (DLT) as defined in the protocol, AEs (adverse events), and treatment-emergent adverse events (TEAEs) at any dose level
The number of participants experiencing a dose-limiting toxicity (DLT) as defined in the protocol, AEs (adverse events), and treatment-emergent adverse events (TEAEs) at any dose level
| Arm | Type | Description |
|---|---|---|
| CX-2051 | EXPERIMENTAL | - |
| CX-2051 + bevacizumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CX-2051 | DRUG | Investigational drug |
| Bevacizumab | DRUG | IV infusion |
Inclusion Criteria: * Metastatic or locally advanced unresectable solid tumor that has progressed after standard therapy * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Measurable disease per RECIST v1.1 * Consent to fresh biopsy or if medically contraindicated, recent (with...